Abstract
Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Current Organic Chemistry
Title: Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators
Volume: 12 Issue: 11
Author(s): Daniel C. Hoessli and Ishtiaq Ahmad
Affiliation:
Abstract: Mistletoe lectin I (ML-I) is a heterodimeric ribosome-inactivating protein composed of a sialic acid-specific Bchain that binds to cell surfaces, and an A-chain with the capacity to depurinate a critical adenosine in the 28S ribosomal RNA. ML-1, in purified or recombinant form, exerts an immunomodulatory effect on neutrophils and macrophages/ monocytes in the low-dose range, while at high doses, it induces apoptosis in both normal and tumoral cells. While mistletoe extracts are widely used as cancer adjuvant therapy, recombinant ML-I (rAviscumin) is a candidate antineoplastic agent that has successfully passed Phase I clinical trials. In immunodeficient mouse models, the efficacy of recombinant ML-I was demonstrated for ovarian carcinoma, melanoma and various hematological malignant cell lines. The clinical potential of recombinant ML-I as a non-mutagenic and non-genotoxic molecule is high and could be used to potentiate classical anti-neoplastic drugs. Its capacity to induce apoptosis in cancer cell lines lacking p53 allows considering its use against genetically unstable and highly metastatic cancers. The mechanisms of apoptosis induced by ML-I probably involves intracellular pathways akin to those described as the “ribotoxic stress response” that directly target the mitochondrion.
Export Options
About this article
Cite this article as:
Hoessli C. Daniel and Ahmad Ishtiaq, Mistletoe Lectins: Carbohydrate-Specific Apoptosis Inducers and Immunomodulators, Current Organic Chemistry 2008; 12 (11) . https://dx.doi.org/10.2174/138527208784892196
DOI https://dx.doi.org/10.2174/138527208784892196 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nampt/Visfatin/PBEF: A Functionally Multi-faceted Protein with a Pivotal Role in Malignant Tumors
Current Pharmaceutical Design Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Current Medicinal Chemistry The ATP-driven Hsp60 Machinery: Biological and Clinical Implications
Current Immunology Reviews (Discontinued) Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Advances in Stem Cell Therapy for Leukemia
Current Stem Cell Research & Therapy Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance
Current Rheumatology Reviews Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Current Medicinal Chemistry A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
Current Gene Therapy Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets Synergy Against Fungal Pathogens: Working Together is Better Than Working Alone
Current Medicinal Chemistry Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion
Current Vascular Pharmacology Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design Targeting Kinases in Cancer Therapies: Adverse Effects on Blood Platelets
Current Pharmaceutical Design Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Natural Compounds in Anti-Leukaemic Therapy: A Review
Mini-Reviews in Medicinal Chemistry Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Current Stem Cell Research & Therapy